Xceleron, a provider of ultra-sensitive Accelerator Mass Spectrometry (AMS) in novel clinical investigations, has partnered with JCL Bioassay, a provider of highly sensitive LC-MS/MS and proprietary methodologies, to offer access to a range of sensitive and robust analytical platforms in early clinical development across Asia, Europe and North America.     The partnership aims to provide access to clinical design expertise and the most appropriate analytical platform for early clinical investiga...